Sign In
Buy NPCE
$15.88
-0.410 (-2.52%)
At Close: Jun 03, 2026
NeuroPace Completes Repurchase of 5.3 Million Shares of Its Common Stock from KCK Ltd.
04:05pm, Thursday, 20'th Feb 2025
MOUNTAIN VIEW, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it h
NeuroPace to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025
04:05pm, Wednesday, 19'th Feb 2025
MOUNTAIN VIEW, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it w
MOUNTAIN VIEW, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE) today announced the completion of its previously announced underwritten public offering of 7,475,000 shares of i
NeuroPace Announces Pricing of Public Offering of $65 Million of Common Stock
06:33am, Friday, 14'th Feb 2025
MOUNTAIN VIEW, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE) today announced the pricing of an underwritten public offering of 6,500,000 shares of its common stock at a publ
NeuroPace Announces Proposed Public Offering of $65 Million of Common Stock
04:34pm, Thursday, 13'th Feb 2025
MOUNTAIN VIEW, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE) today announced that it intends to offer and sell, in an underwritten public offering, $65 million of shares of
MOUNTAIN VIEW, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that
NeuroPace Issues 2025 Financial Guidance Targets
05:15pm, Tuesday, 28'th Jan 2025
– 2025 revenue guidance of $92 million to $96 million – – 2025 gross margin guidance of 73% to 75% – – Three-year targets of 20% revenue CAGR and achievement of cash flow breakeven – M
NeuroPace (NPCE) Soars 9.1%: Is Further Upside Left in the Stock?
06:36am, Wednesday, 22'nd Jan 2025
NeuroPace (NPCE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase i
NeuroPace Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2024 and Provides Business Updates
04:05pm, Wednesday, 08'th Jan 2025
Preliminary unaudited revenue expected to be between $21.0 million and $21.5 million for Q4 2024, and between $79.4 million and $79.9 million for full year 2024
NeuroPace (NPCE) Upgraded to Buy: What Does It Mean for the Stock?
01:01pm, Wednesday, 25'th Dec 2024
NeuroPace (NPCE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
NeuroPace to Present at the 43rd Annual J.P. Morgan Healthcare Conference
04:05pm, Wednesday, 18'th Dec 2024
MOUNTAIN VIEW, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that
NeuroPace to Host Investor Day on January 28th in New York City
04:05pm, Thursday, 12'th Dec 2024
MOUNTAIN VIEW, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that
Wall Street Analysts Think NeuroPace (NPCE) Could Surge 31.47%: Read This Before Placing a Bet
10:55am, Friday, 06'th Dec 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 31.5% in NeuroPace (NPCE). While the effectiveness of this highly sought-after metric is questionable, the posi
NeuroPace to Showcase the RNS System at the 2024 American Epilepsy Society (AES) Annual Meeting
04:05pm, Wednesday, 04'th Dec 2024
RNS System to be featured in over 70 scientific presentations and posters Pre-book a demonstration in the NeuroPace Tech Suite to see the latest innovations of the RNS System which simplify the treatm
NeuroPace Completes Enrollment in Feasibility Study of RNS System for Lennox-Gastaut Syndrome
04:05pm, Tuesday, 03'rd Dec 2024
Enrollment and implant procedures completed in NIH funded feasibility study of LGS, a severe and disabling childhood-onset epilepsy Enrollment and implant procedures completed in NIH funded feasibilit
